10-Q: Intuitive Surgical Reports Strong Q1 2025 Results, Procedure Growth Drives Revenue

Intuitive Surgical's Q1 2025 results show a significant increase in revenue driven by procedure growth and system placements, despite facing potential tariff headwinds.

Summary

• Intuitive Surgical reported a 19% increase in total revenue to $2.25 billion for Q1 2025, compared to $1.89 billion in Q1 2024.
• The company saw a 17% increase in da Vinci procedures, with approximately 732,000 procedures performed in Q1 2025.
• Ion procedures increased by 58%, reaching approximately 30,700 in Q1 2025.
• Instruments and accessories revenue grew by 18% to $1.37 billion.
• Systems revenue increased by 25% to $523 million, with 367 da Vinci systems placed during the quarter.
• The installed base of da Vinci systems reached approximately 10,189, a 15% increase year-over-year.
• Gross profit margin was 64.7%, a slight decrease from 65.9% in Q1 2024.
• Operating income increased by 23% to $578 million.
• The company's cash, cash equivalents, and investments totaled $9.10 billion as of March 31, 2025.
• The company anticipates a significant increase in its cost of revenues for the second half of 2025 due to recently announced and implemented global tariffs.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong financial results and procedure growth. However, potential headwinds from tariffs and increased competition temper the overall sentiment.

Positives

• Strong revenue growth driven by increased procedure volumes and system placements.
• Significant growth in both da Vinci and Ion procedures.
• Expansion of the installed base of da Vinci systems.
• Increased system revenue driven by higher ASPs and operating lease revenue.
• Strong growth in OUS markets, particularly in the UK, India, and South Korea.
• Successful launch of the da Vinci 5 system, with 147 placements in Q1 2025.

Negatives

• Gross profit margin decreased slightly from 65.9% to 64.7%.
• The company anticipates a significant increase in its cost of revenues for the second half of 2025 due to recently announced and implemented global tariffs.
• System demand in China has been adversely impacted by increasing robotic-assisted surgical system competition from domestic companies and, to a lesser extent, a broader central government focus on systematic governance.
• The number of U.S. da Vinci bariatric procedures performed continued to decline in the mid-single digits in the first quarter of 2025 compared to the first quarter of 2024.

Risks

• Potential adverse effects from macroeconomic and geopolitical uncertainties, including tariffs, supply chain challenges, and inflationary pressures.
• Tariffs imposed by the U.S. and China could significantly increase costs and hinder competitiveness.
• Hospitals facing staffing shortages and financial pressures may reduce capital spending.
• Increasing competition in the robotic-assisted surgery market.
• Regulatory risks associated with medical device approvals and compliance.
• Uncertainty regarding the impact of doctor strikes in South Korea on procedure volumes.
• Potential for reduced cash flow from operations due to macroeconomic and geopolitical headwinds.

Future Outlook

The company expects continued growth in procedures and system placements, but anticipates potential headwinds from tariffs, supply chain challenges, and macroeconomic uncertainties. The company expects capital investments to range between $650 million and $750 million in 2025, the majority of which will be facilities-related investments.

Management Comments

• The company is focused on delivering better outcomes, better patient experiences, better care team experiences, lower total cost of care, and expanded access to high-quality minimally invasive care.
• The company believes it is well-positioned to synthesize scientific and technological advances to deliver meaningful value to stakeholders.

Industry Context

The robotic-assisted surgery market is becoming increasingly competitive, with several companies introducing or planning to introduce new systems. Intuitive Surgical faces competition from established players like Medtronic and Johnson & Johnson, as well as emerging companies in China and other regions. The company's success depends on its ability to innovate, maintain its market share, and expand into new procedures and geographies.

Comparison to Industry Standards

• Intuitive Surgical's growth in procedure volume and system placements is generally in line with the overall growth of the robotic-assisted surgery market.
• Competitors like Medtronic and Johnson & Johnson are also investing heavily in robotic surgery platforms, aiming to capture market share.
• Intuitive Surgical's gross profit margin is relatively high compared to other medical device companies, reflecting its strong market position and recurring revenue model.
• The company's R&D spending is significant, indicating its commitment to innovation and maintaining a competitive edge.
• The company's cash reserves provide financial flexibility to pursue acquisitions, strategic partnerships, and other growth initiatives.
• The company's exposure to tariffs and supply chain disruptions is a common challenge for medical device companies with global operations.

Legal Proceedings

• The Company is currently named as a defendant in a number of individual product liability lawsuits filed in various state and federal courts.
• On October 19, 2022, a jury rendered a verdict against the Company awarding $10 million in damages to Rex Medical, L.P. in a patent infringement lawsuit.
• On May 10, 2021, Surgical Instrument Service Company, Inc. (SIS) filed a complaint in the Northern District of California Court alleging antitrust claims against the Company relating to EndoWrist service, maintenance, and repair processes.
• Three class action complaints were filed against the Company in the Northern District of California Court alleging antitrust allegations relating to the service and repair of certain instruments manufactured by the Company.
• On September 18, 2024, Restore Robotics Repairs (Restore) filed a complaint in the United States District Court for the Northern District of Florida alleging antitrust claims against the Company relating to the service and replacement of X/Xi EndoWrist instruments for use with the da Vinci X and Xi surgical systems.

Stakeholder Impact

• Shareholders: Positive impact from strong financial performance and growth prospects.
• Employees: Potential for increased job opportunities and career advancement.
• Customers (Hospitals): Access to innovative surgical technologies and potential for improved patient outcomes.
• Patients: Potential for less invasive surgical procedures and faster recovery times.
• Suppliers: Continued demand for components and materials.
• Creditors: Low risk due to strong financial position and cash reserves.

Next Steps

• Continue phased launch of the da Vinci 5 surgical system.
• Seek additional clearances, approvals, and certifications for the Ion endoluminal system in OUS markets.
• Monitor and mitigate the impact of tariffs and supply chain disruptions.
• Continue to invest in research and development to drive innovation.
• Optimize training pathways and collect additional clinical data for the Ion system in China.
• Continue commercialization of the da Vinci SP surgical system in select major European countries as part of a measured rollout.

Key Dates

Keywords

Intuitive Surgical, da Vinci, Ion, robotic surgery, surgical systems, procedures, revenue, financial results, Q1 2025, tariffs, system placements, installed base